4.6 Review

Premenstrual Dysphoric Disorder: Evidence for a New Category for DSM-5

Journal

AMERICAN JOURNAL OF PSYCHIATRY
Volume 169, Issue 5, Pages 465-475

Publisher

AMER PSYCHIATRIC PUBLISHING, INC
DOI: 10.1176/appi.ajp.2012.11081302

Keywords

-

Categories

Funding

  1. Shire
  2. Canadian Institutes of Health Research
  3. APA
  4. GlaxoSmithKline
  5. Eli Lilly
  6. NIMH
  7. National Institute on Drug Abuse
  8. Medical Research Council [G0801418B] Funding Source: researchfish

Ask authors/readers for more resources

Premenstrual dysphoric disorder, which affects 2%-5% of premenopausal women, was included in Appendix B of DSMIV, Criterion Sets and Axes Provided for Further Study. Since then, aided by the inclusion of specific and rigorous criteria in DSM-IV, there has been an explosion of research on the epidemiology, phenomenology, pathogenesis, and treatment of the disorder. In 2009, the Mood Disorders Work Group for DSM-5 convened a group of experts to examine the literature on premenstrual dysphoric disorder and provide recommendations regarding the appropriate criteria and placement for the disorder in DSM-5. Based on thorough review and lengthy discussion, the work group proposed that the information on the diagnosis, treatment, and validation of the disorder has matured sufficiently for it to qualify as a full category in DSM-5. A move to the position of category, rather than a criterion set in need of further study, will provide greater legitimacy for the disorder and encourage the growth of evidence-based research, ultimately leading to new treatments.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available